Tag: NAION
-
GLP-1 Lawsuits Involving NAION Filed in Federal Court: 200 Cases as of August 2026
Patients Using Ozempic, Wegovy, Rybelsus, Mounjaro, and Zepbound Seek Legal Compensation for Vision Loss (Posted by Tom Lamb at Drug Injury Watch) In December 2025, GLP-1 lawsuits involving NAION filed in federal court were consolidated by the…
-
Ozempic And Other GLP-1RA Use Associated With NAION Eye Side Effect
New 2026 Medical Article Published By JAMA Network Open Investigates Drug Safety Issue (Posted by Tom Lamb at Drug Injury Watch) An increasingly known but still-developing drug safety issue is that of Ozempic and other GLP-1RA use…
-
Wegovy and Ozempic Vision Loss: Wegovy Rate 5x Higher vs. Ozempic, Men 3x More Often vs. Women
Non-arteritic Anterior Ischemic Optic Neuropathy (NAION) Semaglutide Study 2026 Data Analysis (Posted by Tom Lamb at Drug Injury Watch) A March 2026 British Journal of Ophthalmology medical journal article, “Ischemic optic neuropathy with semaglutide: global observational analysis…
-
While Rybelsus Pills Are Being Replaced With Pills Called Ozempic, Semaglutide NAION Risk Remains
But the January 2026 Rybelsus-Ozempic Drug Label Still Has No Warnings for NAION Vision Loss Side Effect (Posted by Tom Lamb at Drug Injury Watch) The “Revised: 1/2026” Prescribing Information document for “RYBELSUS and OZEMPIC tablets” caused…
-
Risk of NAION With Semaglutide Medicines is 2 Times Higher Than SGLT2i Diabetes Drugs
2026 Medical Article Links NAION to Ozempic, Wegovy, and Rybelsus, Again, With New Study (Posted by Tom Lamb at Drug Injury Watch) This drug safety issue of non-arteritic anterior ischemic optic neuropathy (NAION) associated with semaglutide-containing drugs…
-
NAION Eye Side Effect for Ozempic and Mounjaro: Drug Injury Lawsuits Update January 2026
Federal Court MDL: IN RE: Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs) Non-Arteritic Anterior Ischemic Optic Neuropathy Products Liability Litigation (Posted by Tom Lamb at Drug Injury Watch) In December 2025, the U.S. Judicial Panel on Multidistrict Litigation…
-
Wegovy and Ozempic Increase NAION Risk, an Eye Side Effect That Can Result in Blindness
Semaglutide is the Active Ingredient in These GLP-1 Drugs Used for Diabetes or Weight Loss (Posted by Tom Lamb at Drug Injury Watch) Over the past year, we have written several articles that reference medical reports concerning…
-
More Evidence For Increased Risk of NAION With Ozempic or Mounjaro in Diabetes Patients
NAION is Likely Associated With Other Semaglutide or Tirzepatide GLP-1RA Drugs Used for Weight Loss (Posted by Tom Lamb at Drug Injury Watch) A new medical article published August 11, 2025, online by JAMA Network…
-
Current FDA Safety Investigation: NAION With Mounjaro, Zepbound, and Other GLP-1 RAs
Evaluating Glucagon-like Peptide-1 (GLP-1) Receptor Agonists for Possible Risk of NAION Side Effects (Posted by Tom Lamb at Drug Injury Watch) The FDA has been investigating "potential signals" of non-arteritic anterior ischemic optic neuropathy (NAION)…